1784 Stock Overview
Provides cord blood banking services in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BIONET Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$92.80 |
| 52 Week High | NT$162.01 |
| 52 Week Low | NT$52.01 |
| Beta | 0.71 |
| 11 Month Change | -3.53% |
| 3 Month Change | -13.58% |
| 1 Year Change | 70.76% |
| 33 Year Change | 135.50% |
| 5 Year Change | 122.83% |
| Change since IPO | 599.94% |
Recent News & Updates
Shareholder Returns
| 1784 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | 6.8% | 0.9% | 0.8% |
| 1Y | 70.8% | -9.1% | 30.3% |
Return vs Industry: 1784 exceeded the TW Healthcare industry which returned -9.1% over the past year.
Return vs Market: 1784 exceeded the TW Market which returned 30.3% over the past year.
Price Volatility
| 1784 volatility | |
|---|---|
| 1784 Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1784 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1784's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | n/a | www.bionetcorp.com |
BIONET Corp. provides cord blood banking services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC + immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products.
BIONET Corp. Fundamentals Summary
| 1784 fundamental statistics | |
|---|---|
| Market cap | NT$4.70b |
| Earnings (TTM) | NT$55.72m |
| Revenue (TTM) | NT$1.18b |
84.3x
P/E Ratio4.0x
P/S RatioIs 1784 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1784 income statement (TTM) | |
|---|---|
| Revenue | NT$1.18b |
| Cost of Revenue | NT$529.73m |
| Gross Profit | NT$648.00m |
| Other Expenses | NT$592.27m |
| Earnings | NT$55.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 55.02% |
| Net Profit Margin | 4.73% |
| Debt/Equity Ratio | 3.0% |
How did 1784 perform over the long term?
See historical performance and comparison